MedPath

Adoptive immunotherapy using donor liver graft derived natural killer (NK) cells for preventing severe infection after liver transplantatio

Not Applicable
Recruiting
Conditions
decompensated liver cirrhosis patients who will receive liver transplantation
Registration Number
JPRN-UMIN000019183
Lead Sponsor
Hiroshima University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
37
Inclusion Criteria

Not provided

Exclusion Criteria

1) patients who will receive re-transplantation 2) patients who will receive deceased donor liver transplantation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of blood stream infection during one month after liver transplantation
Secondary Outcome Measures
NameTimeMethod
1. Overall survival (6 months, 1 and 3 years) 2. Effect on immunological reaponse after liver transplantation 3. Incidence of recurrence of hepatocellular carcinoma and de novo malignancy 4. Incidence of other infectious disease 5. Safety evaluation
© Copyright 2025. All Rights Reserved by MedPath